1. Home
  2. WDI vs ALLO Comparison

WDI vs ALLO Comparison

Compare WDI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WDI
  • ALLO
  • Stock Information
  • Founded
  • WDI 2021
  • ALLO 2017
  • Country
  • WDI United States
  • ALLO United States
  • Employees
  • WDI N/A
  • ALLO N/A
  • Industry
  • WDI Trusts Except Educational Religious and Charitable
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • WDI Finance
  • ALLO Health Care
  • Exchange
  • WDI Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • WDI 786.7M
  • ALLO 677.5M
  • IPO Year
  • WDI N/A
  • ALLO 2018
  • Fundamental
  • Price
  • WDI $14.76
  • ALLO $2.20
  • Analyst Decision
  • WDI
  • ALLO Buy
  • Analyst Count
  • WDI 0
  • ALLO 12
  • Target Price
  • WDI N/A
  • ALLO $10.06
  • AVG Volume (30 Days)
  • WDI 192.6K
  • ALLO 2.6M
  • Earning Date
  • WDI 01-01-0001
  • ALLO 11-07-2024
  • Dividend Yield
  • WDI 11.80%
  • ALLO N/A
  • EPS Growth
  • WDI N/A
  • ALLO N/A
  • EPS
  • WDI 1.12
  • ALLO N/A
  • Revenue
  • WDI N/A
  • ALLO $43,000.00
  • Revenue This Year
  • WDI N/A
  • ALLO N/A
  • Revenue Next Year
  • WDI N/A
  • ALLO N/A
  • P/E Ratio
  • WDI $12.82
  • ALLO N/A
  • Revenue Growth
  • WDI N/A
  • ALLO 26.47
  • 52 Week Low
  • WDI $12.16
  • ALLO $1.99
  • 52 Week High
  • WDI $14.69
  • ALLO $5.78
  • Technical
  • Relative Strength Index (RSI)
  • WDI 38.17
  • ALLO 35.38
  • Support Level
  • WDI $14.51
  • ALLO $1.99
  • Resistance Level
  • WDI $14.86
  • ALLO $3.36
  • Average True Range (ATR)
  • WDI 0.16
  • ALLO 0.20
  • MACD
  • WDI -0.01
  • ALLO -0.09
  • Stochastic Oscillator
  • WDI 34.25
  • ALLO 10.72

About WDI Western Asset Diversified Income Fund of Beneficial Interest

Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: